Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials.gov

References

• Ager BJ, Gallardo-Rincón D, de León DC, Chávez-Blanco A, Chuang L, Dueñas-González A, et al. 2018. Advancing clinical research globally: cervical cancer research network from Mexico. Gynecologic Oncology Reports 25:90–93.
   PubMed Web of Science ®Google Scholar
• Bashir R, Dunn AG. 2016. Systematic review protocol assessing the processes for linking clinical trial registries and their published results. BMJ Open 6:e013048.
   PubMed Web of Science ®Google Scholar
• Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A, et al. 2012. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010’. JAMA 307:1838–1847.
   PubMed Web of Science ®Google Scholar
• Canadian Cancer Scociety. 2018. Chemotherapy for cervical cancer, Canadian Cancer Scociety. Available from: http://www.cancer.ca/en/cancer-information/cancer-type/cervical/treatment/chemotherapy/?region=on(http://www.cancer.ca/en/cancer-information/cancertype/cervical/treatment/chemotherapy/?region=on
   Google Scholar
• Cetina L, Coronel J, Duen A, Cervantes-madrid D. 2012. Emerging drugs for cervical cancer. Expert Opinion Emerging Drugs 17: 203–218.
   Google Scholar
• Cetina L, Crombet T, Jiménez-Lima R, Zapata S, Ramos M, Avila S, et al. 2015. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy 16:684–689.
   PubMed Web of Science ®Google Scholar
• Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, et al. 2017. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG oncology/gynecologic oncology – group study. Gynecologic Oncology 146:554–559.
   PubMed Web of Science ®Google Scholar
• Chen YJA, Del Priore G. 2015. The role of cisplatin alternative regimens with radiotherapy in cervical cancer. Gynecologic Oncology Reports 11:38–40.
   PubMed Web of Science ®Google Scholar
• Cristina A, Rachele DM, Reisner G, Erlich F, Fontes MS, Moralez G. 2016. A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemotherapy and Pharmacology 78:101–109.
   Google Scholar
• Davidson S. 2011. Treatment for advanced cervical cancer: impact on quality of life’. Critical Reviews in Oncology/Hematology 79:24–30.
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Serrano-Olvera A, Cetina L, Coronel J. 2014. New molecular targets against cervical cancer. International Journal of Women’s Health 6:1023–1031.
   PubMedGoogle Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro J-M, Buqué A, Senovilla L, Baracco EE, et al. 2014. Classification of current anticancer immunotherapies’. Oncotarget 5:12472–12508.
   PubMed Web of Science ®Google Scholar
• Glass HE, Glass LM, Difrancesco JJ. 2015. ClinicalTrials.gov: an underutilized source of research data about the design and conduct of commercial clinical trials. Therapeutic Innovation & Regulatory Science 49:218–224.
   PubMed Web of Science ®Google Scholar
• Green J, Kirwan J, Tierney J, Symonds P, Fresco L, Williams C, et al. 2001. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane Database of Systematic Reviews CD002225.
   PubMedGoogle Scholar
• Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang X-Y, et al. 2013. Therapeutic cancer vaccines: past, present, and future. Advances in Cancer Research 119:421–475.
   PubMed Web of Science ®Google Scholar
• Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, et al. 2013. Characteristics of oncology clinical trials. JAMA Internal Medicine 173:972–979.
   PubMed Web of Science ®Google Scholar
• Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW, Shingleton HM, Blessing JA, et al. 1979. Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. International Journal of Radiation Oncology, Biology, Physics 5:317–322.
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Hoskins W, Small W, Thomas GM, Trimble EL. 2010. The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. International Journal of Gynecological Cancer 20:1092–1100.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Andrews SJ, Moore KN, Chon HS, Ivy SP. 2019. Randomized phase II trial of triapine-cisplatin-radiotherapy for locally advanced stage uterine cervix or vaginal cancers . Frontiers in Oncology 9:1067.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, et al. 2013. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers . Gynecologic Oncology 130:75–80.
   PubMed Web of Science ®Google Scholar
• Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, et al. 2010. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clinical Cancer Research 16:1298–1306.
   PubMed Web of Science ®Google Scholar
• Li K, Shi M, Qin S. 2018. Current status and study progress of recombinant human endostatin in cancer treatment. Oncology and Therapy 6:21–43.
   PubMed Web of Science ®Google Scholar
• Longoria TC, Tewari KS. 2015. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations. Drugs 75:1853–1865.
   PubMed Web of Science ®Google Scholar
• Malkasian GD, Decker DG, Mussey E, Johnson CE. 1964. Preliminary observations on carcinoma of the cervix treated with 5-fluorouracil. American Journal of Obstetrics and Gynecology 88:82–85.
   PubMed Web of Science ®Google Scholar
• Maria J, Prat A, Gil-moreno A, Pérez J, Parera M. 2008. Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:S72–S76.
   Google Scholar
• Matulonis UA, Wright A, Campos S, Konstantinopoulos P, Peralta A, MacNeill K, et al. 2017. A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT142.
   Google Scholar
• Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, et al. 2016. Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a phase 1 clinical study. International Journal of Radiation Oncology, Biology, Physics 94:111–117.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Takabe Y, Watanabe M, Terasima T. 1978. Effectiveness of a sequential combination of bleomycin and mitomycin-c on an advanced cervical cancer. Cancer 41:403–414.
   PubMed Web of Science ®Google Scholar
• Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, et al. 2012. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: a gynecologic oncology group study. Gynecologic Oncology 127:456–461.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Wolchok JD. 2014. Immune checkpoint blockade. Hematology/Oncology Clinics of North America 28:585–600.
   PubMed Web of Science ®Google Scholar
• NCT00025233. 2002. Bevacizumab in treating patients with persistent or recurrent cancer of the cervix [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00049556. 2002. Gefitinib in treating patients with cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00101192. 2004. Cetuximab and cisplatin in treating patients with advanced, persistent, or recurrent cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00104910. 2005. Cetuximab, cisplatin, and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00389974. 2007. Sunitinib malate in treating patients with uterine cervical cancer that is stage IVB, recurrent, or cannot be removed by surgery [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00430781. 2006. Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00499031. 2007. Cetuximab in treating patients with persistent or recurrent cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00518193. 2007. Phase II study, association of cisplatine topotecan and cetuximab in patients whith late or in progress epithelial cancer of the cervix (ERBUS) [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00803062. 2008. Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT00997009. 2009. Study of adding cetuximab to chemotherapy for the treatment of advanced and/or recurrent cervical cancer (MITO CERV 2) [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• NCT02095119. 2008. A monoclonal antibody, nimotuzumab, as treatment for recurrent or metastatic cervical cancer [Internet]. Available from: ClinicalTrials.gov
   Google Scholar
• Oaknin A, Rodriguez-freixinos V. 2016. Bevacizumab in the treatment of cervical cancer – current evidence and next steps. European Oncology & Haematology 12:32–43.
   Google Scholar
• Panesar K, Hons B. 2015. Stage-based treatment for cervical cancer. US Pharm 40:HS5–HS9.
   Web of Science ®Google Scholar
• Caruso C. 2018. Pembrolizumab OK'd for cervical cancer. Cancer Discovery 8:904.
   Google Scholar
• Peng H, Chen L, Chen Y-P, Li W-F, Tang L-L, Lin A-H, et al. 2018. The current status of clinical trials focusing on nasopharyngeal carcinoma: a comprehensive analysis of ClinicalTrials.gov database’. PLoS One 13: e0196730.
   PubMed Web of Science ®Google Scholar
• Pfaendler KS, Tewari KS. 2016. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 214:22–30.
   PubMed Web of Science ®Google Scholar
• Piver MS, Barlow JJ, Vongtama V, Webester J. 1974. Hydroxyurea and radiation therapy in advanced cervical cancer. American Journal of Obstetrics and Gynecology 120:969–972.
   PubMed Web of Science ®Google Scholar
• Piver MS, Barlow JJ, Vongtama V, Blumenson L. 1977. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. American Journal of Obstetrics and Gynecology 129:379–383.
   PubMed Web of Science ®Google Scholar
• Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, et al. 2016. Advances and concepts in cervical cancer trials: a road map for the future. International Journal of Gynecological Cancer 26:199–207.
   PubMedGoogle Scholar
• Schmid BC, Oehler MK. 2015. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Current Treatment Options in Oncology 16:318.
   PubMed Web of Science ®Google Scholar
• Seoud M, Lundqvist EÅ, Fujiwara K. 2015. Targeted therapy in gynecologic cancers: ready for prime time? International Journal of Gynaecology and Obstetrics131 Suppl 2:S150–S152.
   PubMed Web of Science ®Google Scholar
• Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, et al. 2011. Epidermal growth factor receptor as a biomarker for cervical cancer. Annals of Oncology 22:2166–2178.
   PubMed Web of Science ®Google Scholar
• Symonds RP, Gourley C, Davidson S, Carty K, McCartney E, Rai D, et al. 2015. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet. Oncology 16:1515–1524.
   PubMed Web of Science ®Google Scholar
• Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, et al. 2017. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Annals of Oncology 28:505–511.
   PubMed Web of Science ®Google Scholar
• Tipples K, Powell M. 2011. Clinical trials in cervical cancer. In: Kehoe S, Edmondson RJ, Gore M, McNeish IA, editors. Gynaecological cancers: biology and therapeutics. Cambridge: Cambridge University Press, p. 223–232.
   Google Scholar
• WHO (ed.). 2014. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: World Health Organization.
   Google Scholar
• Zhang Y, Yang Z, Zhou Y, Pan J, Liu Y. 2015. Efficacy of concurrent single-agent chemotherapy using radiotherapy in patients with cervical cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine 8:8661–8673.
   PubMed Web of Science ®Google Scholar